drugset / Trial / NCT03565367
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
Phase 1
Completed
9 enrolled
Daniel M. Spielman
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This early phase I trial studies how well hyperpolarized carbon C 13 pyruvate magnetic resonance imaging works in detecting lactate and bicarbonate in participants with central nervous system tumors. Hyperpolarized carbon C 13 pyruvate magnetic resonance imaging may be used to measure the metabolic state of malignant brain tumors.
Timeline
- Start
- 2018-11-06
- Primary completion
- 2019-06-20
- Completion
- 2019-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | — | Intravenous |